Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00229268 · ClinicalTrials.gov registry record
Research on the Nature, Diagnosis, and Treatment of Obesity and Diabetes
A clinical trial, sponsored by Rockefeller University.
- Completed
- Registry status
- 14
- Enrollment target
NCT00229268: Completed study, sponsored by Rockefeller University.
NCT00229268 is a clinical trial that has completed, run by Rockefeller University. The registered enrollment target is 14 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00229268 has completed, sponsored by Rockefeller University.
- COMPLETED
- Registry status
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the level of FOXA2 expression in fat tissue is a biomarker of insulin resistance. To test this hypothesis, we will perform euglycemic-hyperinsulinemic clamps in normal and obese human subjects to calculate insulin sensitivity, and see if insulin sensitivity correlates with the FOXA2 expression in subcutaneous fat.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2005-09 |
| Est. Completion | 2010-04 |
What the finished NCT00229268 record still lists
NCT00229268 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 14 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00229268 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00229268 about?
NCT00229268 is a clinical study titled "Research on the Nature, Diagnosis, and Treatment of Obesity and Diabetes". The purpose of this study is to determine whether the level of FOXA2 expression in fat tissue is a biomarker of insulin resistance. To test this hypothesis, we will perform euglycemic-hyperinsulinemic clamps in normal and obese human subjects to calculate insulin sensitivity, and see if insulin sens...
What is the current status of trial NCT00229268?
This trial is currently completed. The enrollment target is 14 participants. The study started on 2005-09. Estimated completion is 2010-04.
Who is sponsoring clinical trial NCT00229268?
This trial is sponsored by Rockefeller University, which has 117 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia